Sanofi gets CDSCO approval for haemophilia bleeding-prevention drug
In short
Sanofi India got CDSCO approval for a drug that helps prevent bleeding in haemophilia patients. The approval covers adults and teenagers aged 12 and older, with or without factor VIII or IX inhibitors.
This matters for patients who may get another treatment option. The reporting does not say when the drug will be launched or how much it will cost.
What the reporting says
Sanofi India received CDSCO approval for a drug to prevent bleeding in haemophilia patients. The publisher summary says the approval covers adults and adolescents aged 12 and above, with or without factor VIII or IX inhibitors. The immediate consequence is regulatory clearance for the treatment in the specified patient groups, while commercial launch timing and pricing are not stated.
Why it matters
Sanofi India said it has received CDSCO approval for a drug to prevent bleeding in haemophilia patients, and the clearance covers adults and adolescents aged 12 and above, with or without factor VIII or IX inhibitors. This gives the company a regulatory green light in India for that patient group. The report does not state launch timing, sales expectations or pricing.